Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy-Reference-Cited by-同舟云学术

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

Published:2014-03-05 Issue:226 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Zamarin Dmitriy¹²³,Holmgaard Rikke B.¹³,Subudhi Sumit K.⁴,Park Joon Seok⁵⁶,Mansour Mena⁷⁸,Palese Peter⁷,Merghoub Taha¹³,Wolchok Jedd D.¹²³⁹,Allison James P.⁴

Affiliation:

1. Swim Across America Laboratory, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA.

2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

3. Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

4. Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY 10065, USA.

6. Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.

7. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

8. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

9. Weill Cornell Medical College and Graduate School of Medical Sciences of Cornell University, New York, NY 10065, USA.

Abstract

Intratumoral treatment with an oncolytic virus results in inflammatory infiltrates in distant tumors and sensitizes the tumors to immune-mediated rejection in the setting of immunotherapy with CTLA-4 blocking antibodies.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Enhancement of Antitumor Immunity by CTLA-4 Blockade

5. Combination immunotherapy of B16 melanoma using anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.;van Elsas A.;J. Exp. Med.,1999

Cited by 600 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy;Clinical and Experimental Medicine;2024-08-28

2. Immunotherapy for small cell lung cancer: the current state and future trajectories;Discover Oncology;2024-08-16

3. 15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN;2024-08-09

4. Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review;Frontiers in Immunology;2024-07-24

5. Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence;Cureus;2024-07-24